Corvex, Inc.

Good afternoon, everybody, and thank you for joining us today. Our CEO, John Masters de Tarro, will open today's call with prepared remarks about the progress we've made during the first quarter of 2022. Afterward, I'll cover the highlights of our quarterly operating results and provide perspective on our financial position. Finally, Movano's founder and chief technology officer, Michael Liebman, will join John and me for the Q&A. Before we begin, I'd like to remind everyone that we will make forward-looking statements during today's call. Whether in prepared remarks or during the Q&A session, these forward-looking statements are subject to inherent risks and uncertainties. These risks and uncertainties are detailed in the risk factors section of our filings with the Securities and Exchange Commission, specifically in the company's forms 10Q and 10K. Except as otherwise required by federal securities laws, Movano disclaims any obligation to update or make revisions to such forward-looking statements contained herein or elsewhere to reflect changes in expectations with regards to those events, conditions, and circumstances. Now, I would like to turn the call over to our CEO, John Mastricitaro.

Welcome, everyone. We appreciate you joining us for our first quarter earnings call. In my 30-plus years in the healthcare industry, I've led teams that have brought numerous novel medical devices to the market, which have significantly improved the lives of people with chronic conditions. While those initiatives were certainly rewarding, I believe the technology we're currently developing at Movado is some of the most cutting edge and exciting I've had the pleasure to work on throughout my career. What excites me most is the opportunity we have in front of us, the opportunity to positively impact a much broader range of people, the hundreds of millions of individuals globally who have or are at risk of getting diabetes or hypertension, or who just aren't feeling like themselves and want to regain control of their well-being and bring back their vitality. Consumers are more aware of their health today than ever before, and in general, we collectively understand that to feel our best as we age, we need to put more emphasis on making healthy day-to-day decisions. Since announcing the Movano Ring at CES this year, we continue to receive many messages each week from people who are looking for a way to interpret their body's signals and understand how they can implement changes to feel better and ultimately position themselves to achieve a more well-balanced, healthier, and happier life. To overcome the rising rates of chronic conditions worldwide and the associated and overwhelming healthcare costs, we need technology that promotes prevention and does so in fresh, consumer-friendly ways. At Movano, we're developing technology that combines the best of the consumer and medical worlds to provide equitable access to health data with timely feedback through beautifully designed products. We're moving healthcare technology in a direction that's more accessible, both in price and in experience, arming consumers with medically validated data and key insights they can trust and packaging it into a solution that looks good, feels good, and provides real value so it becomes a seamless part of their everyday life. Our first product is being developed for women because we wanted to offer a solution that addresses a significant gap in the healthcare space. While at this juncture we can't reveal all the features of the Movano Ring for competitive reasons, we can assure you that it is going to be anything but a Me Too product. And our future plans are to develop solutions for everyone, as well as provide additional form factors that support the way people manage and think about their health. 2022 has proven to be a year of significant growth for our company. We're making major strides on the path to launching our first commercial product, the Movano Ring. And today, we want to share some of the highlights from Q1 and recent weeks to demonstrate this progress. As of our last earnings call in March, we had received our single chips back from Global Foundries and were just beginning to conduct testing. We expected the testing to last through the spring. And as you may have read in our press release today, we successfully validated the functionality of our proprietary and patented system on a chip in a timeline we previously outlined. At 4 millimeters by 6.7 millimeters, the system on a chip combines multiple antennas and a variety of frequencies in the smallest ever radio frequency enabled integrated circuit designed specifically for blood pressure or glucose monitoring systems. Reaching this point is one of the most important milestones we have achieved as a company to date. While most competitors in the wearable technology sector use off-the-shelf components, we developed our sensing system from the ground up because we strongly believe the standard approach cannot deliver the level of accuracy flexibility of form factor, or cost we're aiming to achieve. Our integrated sensor uses millimeter wave RF frequencies, which offers an opportunity for increased accuracy across a broader population because it is not affected by different skin pigmentation, as can be the case with optical sensors. In addition, our solution is fabricated using the latest processes and semiconductor technology, meaning the size can be smaller and the materials more cost-effective, giving us greater flexibility in the design of future medical devices and in our ability to offer a solution that's affordable so we can reach a larger, more diverse segment of people. This decision came at no small cost. We've spent more than four years developing, designing, and shrinking this novel, non-invasive technology. Our unique investment in R&D, which has been led by engineers with decades of experience in RF, highlights our commitment to providing more accurate data in unique, small, and affordable form factors. The completion of testing coincides with the addition of one new patent issued to Movano, making a total of seven US patents in our portfolio. The new patent protects innovations around Movano's multi-band chip design, which uses signal diversity and advanced signal processing capabilities, and will be integrated into various devices in the future. While the sensor is now operational, we're integrating it into a new prototype system, which will be closer in size and shape to our final product and will be used for additional blood pressure and glucose studies in the near term. With a smaller prototype, we'll be able to conduct longer and more complex studies that will help us gather additional data to further improve our algorithms. Every time we've sized down from a larger prototype system to something smaller, We've improved upon the cleanliness of the data and our ability to process and filter the data, and we believe this will be the case in this instance as well. In addition to conducting more glucose and blood pressure studies, we've got a busy schedule of other clinical trials for the remainder of the year. We'll be pursuing clearances on our heart rate, blood oxygen saturation, and respiration rate monitoring capabilities and conducting the necessary studies to do so. We believe our decision to pursue FDA clearances to give users medically validated data is a major point of differentiation amongst the competition, and we are taking an aggressive approach to achieve these goals as soon as possible. We continue to position ourselves for the successful launch of the Mobato Ring and future medical devices on the personnel front as well. We've recently added two key members to the team, In April, Nan Kirsten Forte, a pioneer in the healthcare media industry with a track record of success in marketing, partnerships, go-to-market execution, and mergers and acquisitions, joined our board of directors. Over her 30-year career, Nan has been an entrepreneur in successful startups and an entrepreneur at public companies such as WebMD and now at Everyday Health Group. Nan is fiercely passionate about the healthcare space and has many accomplishments, including over 100 awards for health journalism and groundbreaking health and wellness programs. She also spearheaded the development of WebMD Symptom Checker and helped grow the WebMD audience from 1 million to over 120 million monthly users. Additionally, we've hired Chief Marketing Officer Tyler Bucher, Tyler brings over two decades of experience building and launching global integrated consumer marketing campaigns for top-tier brands. In her most recent role as Senior Vice President of Marketing for Hydro, maker of the leading at-home connected rower, she successfully launched the company's first full funnel brand campaign, doubling brand awareness and contributing to its impressive revenue growth. Prior to Hydro, Tyler held various brand strategy and marketing leadership roles at Hasbro and 20th Century Fox. As Movano's CMO, Tyler will oversee the company's brand, communication, and marketing strategies, as well as work cross-functionally to develop partnerships and sales strategies. Between Nan, Tyler, and recent hires Stacey Saldi, our VP of Strategy, who is a former Google and Fitbit employee, and Michael Soule, our VP of Business Development, who has experience in managing global sales, strategy, and new business development at notable consumer product and medical device companies. We're developing a world-class team with tremendous experience bringing new products to the market. They are currently planning for our limited beta release, as well as putting the foundation in place to prepare for a broader market launch following a successful beta program. To help accelerate go-to-market strategy, we're continuing to have conversations with potential strategic partners. We are so fortunate to have Nan and several others on our team who have a wealth of knowledge and experience executing partnerships, which we will draw upon to guide us through the process. Overall, we feel great about our discussions today and the level of interest from potential strategic partners. As we've noted in the past, Given our positioning at the intersection of medical and consumer devices, we believe there are several healthcare and consumer subsectors that would be a great fit for Movano's solution. In summary, the progress we've made over the past year has been exceptional. Since the IPO last March, we've more than doubled our team and brought on a new board member to augment our go-to-market strategies. We've taped out and miniaturized our multi chip architecture into a single sensor solution, which is now functional, patented, and ready to be implemented into a new prototype system. We completed multiple blood pressure studies in our own lab, as well as another glucose pilot study with the help of an independent FDA compliant clinical lab. We've announced and are actively planning for our first data release. The company is also beginning to make a name for itself in the industry. We have recently joined the American Heart Association Center for Health Technology and Innovations Innovators Network so we can leverage their network investing class science from the AHA to help fulfill our company goals. And we are continuing to find opportunities to increase our visibility amongst investors, consumers, and partners. We have accomplished much over the course of the past year with a very small but talented team And I'm looking forward to seeing what we can achieve this next year as we continue to invest in our technology, grow our team, and deepen our commitment to our mission and goals. With that, I'll turn it back to Jay to discuss the quarterly financials.

Thanks, John. We detailed the financial results in today's first quarter earnings release, which you can find on our website, but I'll share a few key line items. Movana reported an operating loss of $6.9 million in the first quarter of 2022 compared to an operating loss of $3.3 million in the year-ago period. The increase was primarily related to the expansion of our team and R&D initiatives, as well as the full quarter inclusion of public company costs related to our March 2021 initial public offering. At the end of the first quarter of 2022, we had $27.7 million of cash, cash equivalents, and short-term investments and total assets of $29.6 million. We will not be providing specific financial guidance, but as you've heard in today's quarterly report, as well as through our commentary on previous quarterly calls, we're making great progress and doing so on a capital-efficient basis. As evidenced by today's news regarding the successful validation of the functionality of a proprietary and patented system on the chip, our plans for several more clinical studies in 2022 as we pursue a wide range of FDA clearances, and the build-out of our go-to-market team, which is positioning the company for a beta release of the Milvano ring in the back half of 2022 and a broader commercial launch following a successful beta program. As that concludes our formal remarks, we'd be glad to take your questions. Operator, we're ready to begin the Q&A section of the call.